目前最快能进入的领域是疫苗,中国药企的研发实力和国外的差距也相对较小,只要通过认证WHO的标准,有望很快进入国外市场近日,诺华公司与中山市政府签订谅解备忘录,将增资2500万美元加大市场开发,把诺华山德士中山工厂建设成为国内最大的仿制药生产基地,预计年销售额将达100亿元。这意味着在金融危机影响、世界经济不振,全球医药行业增速放缓的大背景下,以诺华为代表的跨国巨头也开始深挖中国仿制药市场。 As soon as possible, the fastest field to enter is the vaccine. The research and development strength of Chinese pharmaceutical enterprises and the gap between foreign countries are relatively small. As long as the standards of the certification WHO are approved, it is expected to quickly enter foreign markets Recently, Novartis signed a memorandum of understanding with Zhongshan Municipal Government, Will increase capital 25 million US dollars to increase market development, the Novartis Taxus Zhongshan factory building into the largest generic drug production base, estimated annual sales will reach 10 billion yuan. This means that in the context of the financial crisis, the world economy is sluggish and the global pharmaceutical industry is slowing down, the multinational giants represented by Novartis are also digging into the Chinese generic drug market.